What is HC Wainwright’s Forecast for SAGE Q1 Earnings?

Sage Therapeutics, Inc. (NASDAQ:SAGE) – Investment analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for Sage Therapeutics in a research note issued on Wednesday, April 30th. HC Wainwright analyst D. Tsao expects that the biopharmaceutical company will earn ($0.82) per share for the quarter. HC Wainwright currently has a “Neutral” rating and a $12.00 target price on the stock. The consensus estimate for Sage Therapeutics’ current full-year earnings is ($3.52) per share. HC Wainwright also issued estimates for Sage Therapeutics’ Q2 2026 earnings at ($0.84) EPS, Q3 2026 earnings at ($0.68) EPS and Q4 2026 earnings at ($0.68) EPS.

Sage Therapeutics (NASDAQ:SAGE) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of ($0.99) by ($0.02). Sage Therapeutics had a negative net margin of 971.50% and a negative return on equity of 68.18%. The business had revenue of $14.06 million for the quarter, compared to the consensus estimate of $14.12 million. During the same quarter last year, the business posted ($1.80) EPS. The business’s revenue for the quarter was up 78.0% on a year-over-year basis.

Several other equities research analysts have also weighed in on SAGE. Needham & Company LLC reissued a “hold” rating on shares of Sage Therapeutics in a research note on Friday, April 25th. Canaccord Genuity Group dropped their price target on Sage Therapeutics from $9.00 to $8.00 and set a “hold” rating on the stock in a research note on Wednesday, February 12th. Piper Sandler reduced their price objective on shares of Sage Therapeutics from $26.00 to $9.00 and set an “overweight” rating for the company in a research note on Thursday, January 2nd. Wedbush reissued a “neutral” rating and issued a $6.00 target price on shares of Sage Therapeutics in a research report on Wednesday, February 12th. Finally, Bank of America started coverage on shares of Sage Therapeutics in a research report on Tuesday, March 11th. They issued an “underperform” rating and a $5.00 price target for the company. Three research analysts have rated the stock with a sell rating, fifteen have given a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $8.81.

Sage Therapeutics Stock Performance

Shares of NASDAQ:SAGE opened at $7.48 on Thursday. The stock has a market capitalization of $459.88 million, a price-to-earnings ratio of -1.14 and a beta of 0.48. Sage Therapeutics has a 1-year low of $4.62 and a 1-year high of $14.31. The company has a 50 day moving average price of $7.54 and a 200 day moving average price of $6.78.

Institutional Investors Weigh In On Sage Therapeutics

Large investors have recently made changes to their positions in the company. Picton Mahoney Asset Management grew its position in Sage Therapeutics by 126.0% in the fourth quarter. Picton Mahoney Asset Management now owns 6,423 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 3,581 shares in the last quarter. GAMMA Investing LLC boosted its holdings in Sage Therapeutics by 16,118.0% in the first quarter. GAMMA Investing LLC now owns 8,109 shares of the biopharmaceutical company’s stock worth $64,000 after purchasing an additional 8,059 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new position in Sage Therapeutics during the fourth quarter worth $49,000. Ieq Capital LLC bought a new position in Sage Therapeutics during the fourth quarter valued at about $57,000. Finally, Merit Financial Group LLC bought a new position in Sage Therapeutics during the first quarter valued at about $87,000. Institutional investors own 99.22% of the company’s stock.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.